Literature DB >> 33390945

A Novel Ex Vivo Model of Aortic Valve Calcification. A Preliminary Report.

Arsenii Zabirnyk1,2, Maria Del Mar Perez3, Marc Blasco3, Kåre-Olav Stensløkken1, Miguel D Ferrer3, Carolina Salcedo3, Jarle Vaage1,2,4.   

Abstract

Background: No pharmacological treatment exists to prevent or stop the calcification process of aortic valves causing aortic stenosis. The aim of this study was to develop a robust model of induced calcification in whole aortic valve leaflets which could be suitable for studies of the basic mechanisms and for testing potentially inhibitory drugs.
Methods: Pig hearts were obtained from a commercial abattoir. The aortic valve leaflets were dissected free and randomized between experimental groups. Whole leaflets were cultured in individual wells. Two growth media were used for cultivation: standard growth medium and an antimyofibroblastic growth medium. The latter was employed to inhibit contraction of the leaflet into a ball-like structure. Calcification was induced in the growth medium by supplementation with an osteogenic medium. Leaflets were cultivated for four weeks and medium was changed every third day. To block calcification, the inhibitor SNF472 (a formulation of the hexasodium salt of myo-inositol hexaphosphate hexasodium salt) was used at concentrations between 1 and 100 µM. After cultivation for four weeks the leaflets were snap frozen in liquid nitrogen and kept at -80 °C until blind assessment of the calcium amount in leaflets by inductively coupled plasma optical emission spectroscopy. For statistical analysis, a Kruskal-Wallis test with Dunn's post-test was applied.
Results: Osteodifferentiation with calcium accumulation was in principle absent when standard medium was used. However, when the antimyofibroblastic medium was used, a strong calcium accumulation was induced (p = 0.006 compared to controls), and this was blocked in a dose-dependent manner by the calcification inhibitor SNF472 (p = 0.008), with an EC50 of 3.3 µM.
Conclusion: A model of experimentally induced calcification in cultured whole leaflets from porcine aortic valves was developed. This model can be useful for studying the basic mechanisms of valve calcification and to test pharmacological approaches to inhibit calcification.
Copyright © 2020 Zabirnyk, Perez, Blasco, Stensløkken, Ferrer, Salcedo and Vaage.

Entities:  

Keywords:  SNF472; aortic valve; calcification; ex vivo model; porcine; whole leaflets

Year:  2020        PMID: 33390945      PMCID: PMC7773652          DOI: 10.3389/fphar.2020.568764

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  4 in total

1.  Melatonin Inhibits NF-κB/CREB/Runx2 Signaling and Alleviates Aortic Valve Calcification.

Authors:  Shao-Jung Li; Wan-Li Cheng; Yu-Hsun Kao; Cheng-Chih Chung; Nguyen Ngoc Trang; Yi-Jen Chen
Journal:  Front Cardiovasc Med       Date:  2022-06-20

2.  Cardiomyogenic Differentiation Potential of Human Dilated Myocardium-Derived Mesenchymal Stem/Stromal Cells: The Impact of HDAC Inhibitor SAHA and Biomimetic Matrices.

Authors:  Rokas Miksiunas; Ruta Aldonyte; Agne Vailionyte; Tadas Jelinskas; Romuald Eimont; Gintare Stankeviciene; Vytautas Cepla; Ramunas Valiokas; Kestutis Rucinskas; Vilius Janusauskas; Siegfried Labeit; Daiva Bironaite
Journal:  Int J Mol Sci       Date:  2021-11-24       Impact factor: 5.923

Review 3.  Models and Techniques to Study Aortic Valve Calcification in Vitro, ex Vivo and in Vivo. An Overview.

Authors:  Maria Bogdanova; Arsenii Zabirnyk; Anna Malashicheva; Daria Semenova; John-Peder Escobar Kvitting; Mari-Liis Kaljusto; Maria Del Mar Perez; Anna Kostareva; Kåre-Olav Stensløkken; Gareth J Sullivan; Arkady Rutkovskiy; Jarle Vaage
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

Review 4.  Aortic valve disease in diabetes: Molecular mechanisms and novel therapies.

Authors:  Ileana Manduteanu; Dan Simionescu; Agneta Simionescu; Maya Simionescu
Journal:  J Cell Mol Med       Date:  2021-09-24       Impact factor: 5.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.